PDMR Shareholding/Share Incentive Plan

Diaceutics PLC
31 May 2023
 

 

31 May 2023

Diaceutics PLC

("Diaceutics" or "the Company")

 

PDMR Shareholding/Share Incentive Plan

 

Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, has been notified that on 30 May 2023, Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Susanne Munksted, Jordan Clark, Julie Browne and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for  employees. These purchases will be made each month until further notice.

 

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

 

 

Enquiries:

 

Diaceutics PLC 


Nick Roberts, Chief Financial Officer 

Via Alma PR 



Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison


Nick Harland


Nick Adams




Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Kieran Breheny


Matthew Young

Kinvara Verdon



About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

 

 DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

  

a.

Position/Status

Chief Precision Medicine Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)


Share purchase:





Price(s)

Volume(s)


0.82 p

183



Conditional share award:



Price(s)

Volume(s)



Nil

183



e.

Date of the transaction

Share purchase and Conditional share award: 30 May 2023

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Conditional share award: Off-Market

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jordan Clark

2

Reason for notification

  

a.

Position/Status

Chief Commercial Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)


Share purchase:





Price(s)

Volume(s)


0.82 p

183



 Matched share award:



Price(s)

Volume(s)



0.82 p

183



e.

Date of the transaction

Share purchase and Matched Share award: 30 May 2023

f.

Place of the transaction

Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange

 

 

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Julie Browne

2

Reason for notification

  

a.

Position/Status

Chief Operations Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)


Share purchase:





Price(s)

Volume(s)


0.82 p

183



 Matched share award:



Price(s)

Volume(s)



0.82 p

183



e.

Date of the transaction

Share purchase and Matched Share award: 30 May 2023

f.

Place of the transaction

Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Nick Roberts

2

Reason for notification

  

a.

Position/Status

Chief Finance Officer and PDMR

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

 

ISIN:  GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)


Share purchase:





Price(s)

Volume(s)


0.82 p

183



 Matched share award:



Price(s)

Volume(s)



0.82 p

183



e.

Date of the transaction

Share purchase and Matched Share award: 30 May 2023

f.

Place of the transaction

Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings